Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed by neurologists, medical directors, and MS specialists are critical to producing optimal long- term outcomes, regimen adherence, safety, and cost-effectiveness of such care. With the costs of caring for an MS patient estimated at up to $50,000 per year, over a lifetime of years, the need to evaluate the evidence basis for efficacy and safety of MS therapies has never been more urgent.